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The Authors Reply: The use of extracorporeal 
means of removing toxic immunoglobulin free 
light chains responsible for cast nephropathy in 
patients with myeloma is controversial. The larg-
est of the three randomized trials to test plasma 
exchange did not show a statistically significant 
difference in the composite outcomes defined by 
the study.1 Unfortunately, this study had many 
limitations, including a lack of a clear clinical or 
histologic definition of myeloma cast nephropa-
thy, the type of renal injury amenable to extra-
corporeal removal of free light chains.2 Two 
other smaller, randomized trials of plasma ex-
change suggested meaningful clinical benefit.3,4 
All three trials were done before the introduction 
of new agents in myeloma. In this context, given 
the recognized adverse impact of renal failure 
on survival, its potential reversibility, and the 
safety of the treatment procedure, we recom-
mend additional trials.
The issue of whether an extended duration of 
dialysis with high-cutoff dialyzers is more effec-
tive than plasma exchange at removing free light 
chains or reversing renal failure is not settled. 
No comparative trials have been conducted to 
date. So far, high-cutoff dialyzers have been 
tested only in in vitro studies and in small un-
controlled clinical trials. Their purported effec-
tiveness in reversing renal failure is primarily in 
patients treated with concurrent chemotherapy 
and having a response to such treatment. Further, 
other researchers report similar rates of reduc-
tion in levels of free light chains between plasma 
exchange and high-cutoff dialyzers when a stan-
dard duration of dialysis is used.5 Thus, the data 
are insufficient to suggest that one method is 
superior to the other.
In terms of the type of chemotherapy, we cur-
rently use bortezomib and dexamethasone in com-
bination with either cyclophosphamide or thalid-
omide in these patients. In our letter, it was not 
our intention to separate the contribution of 
plasmapheresis from bortezomib-based therapy. 
We wholeheartedly agree that a formal clinical 
trial is needed. As Hutchison and colleagues 
mention, recent evidence suggests that the speed 
at which a reduction in levels of free light chains 
occurs may be as important as the amount of 
reduction. We hope that the high rate of renal 
response that we reported will inspire further 
studies of plasma exchange and other methods 
of extracorporeal removal of free light chains as 
adjuvant strategies in modern myeloma therapy.
Nelson Leung, M.D. 
Brian L. Burnette, M.D. 
S. Vincent Rajkumar, M.D.
Mayo Clinic 
Rochester, MN 
rajkumar.vincent@mayo.edu
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Protection against Malaria by MSP3 Candidate Vaccine
To the Editor: In 2007, we conducted a double-
blind, randomized, phase 1b clinical trial 
 (ClinicalTrials.gov number, NCT00452088) using 
the merozoite surface protein 3 (MSP3) vaccine in 
a malaria-endemic area. A total of 45 children who 
were 12 to 24 months of age were randomly as-
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signed in a 1:1:1 ratio to receive three doses (on 
days 0, 28, and 56) of MSP3 at a dose of 15 μg, 
MSP3 at a dose of 30 μg, or hepatitis B vaccine 
at a dose of 10 μg. Details of ethical approval 
(which included approval by the national ethics 
committee of Burkina Faso and written informed 
consent), study vaccines, safety, and immunoge-
nicity results have been reported previously1 (see 
the Supplementary Appendix, available with the 
full text of this letter at NEJM.org). The study was 
sponsored by the African Malaria Network Trust 
through a grant from the European Commis-
sion’s EuropeAid Co-operation. The MSP3 vac-
cine was manufactured by Synprosis, who had no 
role in the conduct of the study or in preparation 
of the manuscript.
The trial was not designed to measure vaccine 
efficacy. However, to monitor safety, passive 
surveillance of all episodes of illness, including 
clinical malaria, was maintained during the en-
suing malaria-transmission season in a blinded 
fashion. Since numerous episodes of malaria 
were recorded, we considered examining the 
possibility of a protective effect induced by the 
MSP3 vaccine. A plan to compare the incidence 
of clinical malaria among the three groups was 
agreed on before the analysis began. Given the 
high transmission rate in the study area (>200 
infected bites per person per year),2 clinical ma-
laria was defined as a temperature of 37.5°C or 
higher in the presence of Plasmodium falciparum 
parasitemia at a density of 5000 parasites per 
microliter or more.3 The risk period analyzed 
was from 4 weeks after the third vaccine dose 
until the end of the transmission season.
The incidence rates of clinical malaria were 
substantially lower in each of the two groups 
that received the MSP3 vaccine (1.2 and 1.9 cases 
per 100 days, respectively), than in the group 
that received the hepatitis B vaccine (5.3 cases 
per 100 days) (P = 0.01) (Fig. 1). Thus, despite the 
small sample size and the high cumulative inci-
dence in all groups, there was some indication 
that MSP3 vaccine protected against clinical ma-
laria, at least in the short term. A sensitivity 
analysis with the use of a threshold density of 
10,000 parasites per microliter showed broadly 
similar results (P = 0.03). The similar incidence 
rates in the two MSP3 vaccine groups are consis-
tent with their similar immune responses.1 
These results are in keeping with the reduction 
in episodes of malaria associated with naturally 
occurring MSP3 antibodies.4
It is unlikely that other efforts to control ma-
laria influenced these results, since this was a 
randomized trial and the assessment of malaria 
was conducted in a blinded fashion. Data from 
the demographic surveillance system indicate that 
insecticide-treated bed nets were used in only 5 to 
10% of households. Neither indoor insecticide 
spraying nor intermittent preventive treatments 
were practiced in the area. The study clinic pro-
vided free diagnosis and treatment 24 hours a 
day, so it is likely that most or all episodes of 
symptomatic malaria were detected. Despite the 
limitations in sample size and study design, we 
believe that the findings of this trial warrant 
further evaluation of this vaccine candidate.
Sodiomon B. Sirima, M.D., Ph.D.
Centre National de Recherche et de Formation sur le Paludisme 
Ouagadougou, Burkina Faso 
s.sirima.cnlp@fasonet.bf
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Figure 1. Kaplan–Meier Plot of the Time to the First 
Episode of Clinical Malaria.
There were 660, 519, and 244 days at risk (until the first 
episode of malaria or the end of the risk period) for  
the 15 patients who received MSP3 at a dose of 15 μg, 
the 15 patients who received MSP3 at a dose of 30 μg, 
and the 15 patients who received hepatitis B vaccine, 
respectively, yielding an incidence rate of 1.2, 1.9, and 
5.3 cases per 100 days, respectively. A total of 8, 10, and 
13 children in these groups had an episode of clinical 
malaria. A log-rank test indicated evidence of a differ-
ence in the incidence rate among the three groups 
(P = 0.01). When a threshold density of 10,000 parasites 
per microliter was used, similar results were obtained 
with periods at risk of 715, 563, and 296 days, respec-
tively, and incidence rates of 1.0, 1.6, and 4.1 cases per 
100 days (P = 0.03). The period of analysis shown here 
starts after full immunization (i.e., 4 weeks after the 
third immunization, when antibody titers peak), and 
 increases to the end of transmission.
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correction
A Problem in Gestation (September 1, 2011;365:843-8). The images 
shown as Figures 1 and 2 in the printed Journal (page 846) were 
swapped: the image for Figure 1 (the MRI scan of the abdomen) 
was incorrectly shown as Figure 2, and the image for Figure 2 
(the ultrasonographic image of the neck) was incorrectly shown 
as Figure 1. The figure legends were also swapped; the figure 
titles were correct. Also, in the boldface paragraph beginning 
“After resection” (page 846), the second sentence should have 
read, “Maintenance doses of 600 mg of calcium carbonate with 
200 IU of vitamin D twice daily were prescribed, in addition to 
400 IU of vitamin D3 daily,” rather than “. . . were prescribed, 
with the addition of vitamin D3 (40 IU daily).” In the paragraph 
beginning “The approach to the management” (page 847), in 
the sentence beginning, “Calcitonin, which is classified,” the 
parenthetical description of a category C medication for preg-
nant patients was incorrect; it should have read, “(i.e., a medica-
tion for which animal studies have shown an adverse effect on 
the fetus, but no adequate, well-controlled studies have been 
conducted in humans; potential benefits may warrant use of the 
drug in pregnant women despite potential risks),” rather than 
“(i.e., a medication for which there is no evidence of harm to the 
fetus in studies in animals but for which no adequate studies 
have been conducted in pregnant women).” We regret the errors. 
The article is correct at NEJM.org.
notices
Notices submitted for publication should contain a mailing 
address and telephone number of a contact person or depart-
ment. We regret that we are unable to publish all notices 
 received. Notices also appear on the Journal’s Web site 
(NEJM.org/medical-conference). The listings can be viewed 
in their entirety or filtered by specialty, location, or month.
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The course will be offered in Rancho Mirage, CA, Feb. 17–20.
Contact Dr. Merle L. Diamond, Diamond Headache Clinic 
Research & Educational Foundation, 1235a North Clybourn 
Ave., Suite 408, Chicago, IL 60610; or call (877) 706-6363 or 
(773) 883-2062; or fax (773) 883-2073; or e-mail info@dhc-fdn 
.org; or see http://www.dhc-fdn.org.
MAyo clinic
The following meetings will be held in Rochester, MN: 
“28th Mayo Clinic Dermatology Symposium: The O’Leary 
Meeting” (Sept. 23 and 24); “A Taste of Tropical Medicine: 
A Global Health Volunteerism Short Preparatory Course” (Oct. 
28 and 29); “Geriatric Update for the Primary Care Provider” 
(Nov. 10); and “21st Annual Mayo Clinic Symposium on Sports 
Medicine” (Nov 11 and 12).
Contact the Mayo School of Continuous Professional Devel-
opment, 200 First St. SW, Rochester, MN 55905; or call (800) 
323-2688 or (507) 284-2509; or fax (507) 284-0532; or see 
http://www.mayo.edu/cme; or e-mail cme@mayo.edu.
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